Novo Nordisk is actively seeking partners to expand its pipeline in all of its areas of interest. The goal, according to Jørn Roland Müller, MD, corporate VP, is to supplement the existing pipeline with compounds of therapeutic interest in various stages of development—including early stage compounds as well as the technologies to generate, modify and formulate protein and peptide therapeutics. Read more »
At BIO-Europe Spring®, DSM Biologics and DSM BioSolutions are interested in partnering their proprietary technology packages as well as their CMO services. “Clients can access DSM’s technology either as a CMO client or by out-licensing the technology to optimize biopharma manufacturing, and so reduce costs and risks,” Karen King, president of DSM Biologics, a business unit of DSM Pharmaceutical Products (DPP), pointed out. Read more »
ERYTECH Pharma’s top priority is to identify the right partner for the European distribution of its innovative late-stage therapeutic product, GRASPA®. That partner will have the appropriate infrastructure and skills to distribute specialty products in hemato-oncology, including expertise in orphan drug products and a strong network with access to key clinical opinion leaders in Europe. Read more »
Currently, nearly 1,400 clinical trials are underway in South Africa by companies eager to reach a diverse, often treatment naive, population. Catherine Lund, founder and managing director of OnQ Research, believes those numbers should increase and stands ready to help them do just that. Read more »
By controlling the taste, bioavailability or timed release of drugs, Aptalis Pharmaceutical Technologies can help drug developers recoup the USD 30 billion lost to the industry each year because of patients not refilling—or never filling—their prescriptions. Controlling these factors also may improve compliance, lower dosage amounts, reduce side effects and improve efficacy as well as extend product life and, in some cases, expand the market for a given drug. Read more »
During the past 18 months, J&J has melded its many pharmaceutical companies into one entity, known as Janssen, the Pharmaceutical Companies of Johnson & Johnson. Now the various companies can align goals and strategies, allowing Janssen to speak with one voice, according to Robert J. Wills, vice president of alliance management, pharmaceuticals group. Read more »
As the biopharmaceutical industry shifts focus from small to large molecules, it needs an efficient way to analyze single cells. Sphere Fluidics is one of a handful of companies that has developed the tools to accomplish that quickly, easily and cost-effectively, providing a viable alternative to fluorescence-activated cell sorting. Read more »
Venture capital is the most expensive form of capital, so companies are advised to be creative in sourcing other types of funding. With the current capital headwinds, creative alternatives may be the only options companies have. Read more »
Newsletter